Sight Sciences' Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use

Sight Sciences Inc SGHT published two-year results of the so-called "Romeo" study of the OMNI Surgical System.

• The OMNI Surgical System technology in standalone and combination-cataract surgery demonstrated that the significant reductions in Intraocular Pressure (IOP) and medication usage observed at 12 months were also witnessed at 24 months. 
• In addition, there were no serious or unanticipated adverse events during the two-year study.
• Patients with mild-moderate glaucoma received outflow restorative procedures enabled with the OMNI Surgical System technology, either during cataract surgery (n = 43) or as a standalone treatment (n = 29). 
• Patients were divided into high-baseline IOP (pre-operative IOP > 18 mmHg, n = 34) and low-baseline IOP cohorts (pre-operative IOP ≤ 18 mmHg, n = 38). 
• Average IOP in the high baseline IOP cohort fell 31% (from 21.9 mmHg to 15.2 mmHg) at two years, which included an average reduction of 28% among combination cataract patients (n = 17) and an average reduction of 33% among standalone patients (n = 17). 
• The study also observed an average 33% reduction in medication usage among all patients at 24 months.
• The OMNI Surgical System enables surgeons to provide minimally invasive, implant-free surgery to reduce IOP in adults with primary open-angle glaucoma.

Price Action: SGHT shares are down 0.43% at $9.28 on the last check Tuesday via Benzinga Pro.